The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the American Association of Cancer Research (AACR) Annual Meeting taking place from 25-30 April,… Read More
Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. The transaction is worth up to a total of $415 million, including an undisclosed upfront payment, potential discovery, development, and commercialisation… Read More
DDW’s Megan Thomas looks at a day in the life of Professor Kristian Reich, Co-Founder and CSO of MoonLake. MT: Can you tell us what you do and what you’re working on at the moment? KR: As Co-Founder and Chief Scientific Officer of MoonLake, an advancing biotechnology company without the… Read More
The American Association of Cancer Research (AACR) Annual Meeting took place from 25-30 April at the McCormick Place Convention Center in Chicago, US. DDW’s Megan Thomas looks at key announcements, presentations and breakthroughs that took place. Presidential commentary On Sunday 27 April, attendees were welcomed at the Opening Ceremony by… Read More
This is the latest episode of the free DDW narrated podcast, titled “An overview on the impact of synthetic biology”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Synthetic biology: Impacting drug discovery” and “Synthetic biology: Innovating in drug… Read More
This is the latest episode of the free DDW narrated podcast, titled “An overview on the impact of synthetic biology”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Synthetic biology: Impacting drug discovery” and “Synthetic… Read More
Akiram Therapeutics, a Swedish biotech company specialising in targeted radiotherapy, has enrolled the first patient in the Phase I clinical trial of its drug candidate 177Lu-AKIR001. The trial is being conducted at Karolinska University Hospital, which also acts as the study sponsor, and marks an important milestone in Akiram’s efforts… Read More
DDW Editor Megan Thomas speaks to Paul Peter Tak, President and CEO of Candel Therapeutics, about the company’s cancer data and its development of next-generation viral immunotherapies targeting solid tumours. MT: Please provide a brief overview of Candel’s pipeline? PT: Candel’s clinical stage pipeline is built on two distinct multimodal… Read More
Advances in cancer therapy have produced powerful treatments that can greatly improve survival – but can also trigger fearsome side-effects. Notably, CAR-T cell therapies can cause cytokine release syndrome (CRS). Managing CRS is an area that is becoming increasingly important to Big Pharma, reports DDW’s Megan Thomas. CAR-T cell cancer… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With Eli Lilly so far winning the race to bring an oral GLP-1 drug… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With Eli Lilly so far winning the race to bring an oral GLP-1 drug… Read More
This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer’s treatments”, “The start-up disrupting… Read More
This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer’s treatments”, “… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week of financial uncertainty for the industry, our round-up focuses on the… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week of financial uncertainty for the industry, our round-up focuses on the… Read More
This is the latest episode of the free DDW narrated podcast, titled “How is precision medicine making its mark in drug discovery?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with… Read More
